Clinical Evidence
The published VIRTUE clinical trial reported improved MoCA scores in patients receiving immersive VR cognitive rehabilitation, a reduced length of stay compared with sham VR, and no serious adverse events.
Published phase 2b RCT
The study evaluated immersive virtual reality as an adjunct to standard care for stroke survivors with documented cognitive deficits. The intervention used realistic virtual Activities of Daily Living, tailored difficulty, and repeated practice to support attention, memory, orientation, and task sequencing.
The headline findings were a median MoCA improvement of +8 points in the severe cognitive impairment group, reduced length of stay compared with sham VR, and no serious adverse events reported.
Study design
The trial was a double-blind, randomised controlled study involving 40 stroke patients with documented cognitive deficits. Participants received either VR-based cognitive rehabilitation alongside standard care or a sham VR intervention as placebo control.
The CorteXR/VIRTUE platform immersed participants in realistic, interactive scenarios designed to simulate activities of daily living, such as preparing a meal or managing transactions in a cafe. Tasks were tailored to individual ability with adjustable difficulty levels.
The primary outcome measure was cognitive improvement assessed using the Montreal Cognitive Assessment at the conclusion of treatment and three months post-randomisation. Secondary measures included satisfaction, safety assessments, and duration of hospital stay.
Participants were randomised between VR-based cognitive rehabilitation and sham VR control conditions, enabling comparison against placebo exposure.
The published study reported median MoCA improvements in intervention groups, with the largest reported change among patients with severe cognitive impairment.
The published study reported a reduction in length of stay for patients receiving VR treatment compared with sham VR, supporting an earlier-discharge and patient-flow message.
The study reported no serious adverse events and high acceptability, with minor issues such as transient dizziness or headset discomfort managed during sessions.
CorteXR demonstrated high levels of safety in the study, with no serious adverse events reported. Patients and healthcare staff rated the system highly for usability, engagement, and satisfaction.
Participants in the intervention group exhibited improvements in cognitive domains including attention, memory, and orientation. Existing material notes that patients with severe cognitive impairments showed the most pronounced gains.
The published trial reported a reduced length of stay for patients receiving VR treatment compared with sham VR. This is an important service-capacity and patient-flow finding.
The trial used VR-based cognitive rehabilitation as a complement to traditional therapy, providing safe, repetitive, and engaging practice environments without requiring additional staffing for every repetition.
Chatterjee, K., Buchanan, A., Cottrell, K., Hughes, S., Day, T.W., and John, N.W., 2022. Immersive virtual reality for the cognitive rehabilitation of stroke survivors. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 30, pp.719-728.
Clinical and outcome claims should be read in the context of the full paper, local clinical judgement, and the intended-use documentation supplied during procurement review.
Clinical safety and NHS assurance
CorteXR is a healthcare technology product, so services also need to understand regulatory status, intended use, clinical safety, information governance, support arrangements, and deployment responsibilities.
For procurement, implementation, or clinical governance review, we provide the detailed evidence pack, including relevant version numbers, registration details, and formal documents.
Ready to explore CorteXR?
See how immersive ADL activities, clinician configuration, and remote progress monitoring can fit into your rehabilitation pathway.